D
Madrigal Pharmaceuticals, Inc. MDGL
$333.91 -$6.89-2.02% NASDAQ
Recommendation
Prev Close
$340.80
Volume
341
Avg Vol (90D)
385,543
Market Cap
$7.52B
Dividend & Yield
--
52-Week Range
$199.40 - $377.46
P/E (TTM)
--
EPS (TTM)
-$22.11
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Madrigal Pharmaceuticals reports Q1 EPS ($3.32), consensus ($3.79)
5/1/2025 - The Fly
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
5/1/2025 - Globe Newswire
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
4/30/2025 - Benzinga
Aquatic Capital Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/30/2025 - MarketBeat
Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL Congress MDGL Stock News
4/29/2025 - GuruFocus
Madrigal Pharmaceuticals announces six presentations at EASL Congress
4/29/2025 - The Fly
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
4/29/2025 - Globe Newswire
Emerald Mutual Fund Advisers Trust Sells 3,031 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/29/2025 - Ticker Report
Tri Locum Partners LP Increases Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/29/2025 - MarketBeat
Lord Abbett & CO. LLC Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/29/2025 - MarketBeat
Adage Capital Partners GP L.L.C. Invests $6.16 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/29/2025 - Ticker Report
Madrigal Pharmaceuticals (MDGL, $331.29) price moved above its 50-day Moving Average on April 28, 2025
4/29/2025 - Tickeron - Stocks
Jump Financial LLC Invests $210,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/28/2025 - Ticker Report
Tower Research Capital LLC TRC Increases Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/28/2025 - MarketBeat
Tower Research Capital LLC TRC Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/26/2025 - Ticker Report
Marshall Wace LLP Sells 62,907 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/26/2025 - MarketBeat
Hood River Capital Management LLC Makes New $39.45 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/25/2025 - MarketBeat
Insiders At Madrigal Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness
4/25/2025 - Simply Wall St
BI Asset Management Fondsmaeglerselskab A S Invests $164,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/25/2025 - Ticker Report
Madrigal Pharmaceuticals (MDGL, $319.93) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 24, 2025
4/25/2025 - Tickeron - Stocks
13,400 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Canada Pension Plan Investment Board
4/25/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
4/25/2025 - TipRanks Financial Blog
Cerity Partners LLC Invests $453,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/25/2025 - MarketBeat
Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying
4/24/2025 - Insider Monkey
Rock Springs Capital Management LP Has $81.84 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$180.13M
EBITDA (TTM)
-$496.78M
EBIT (TTM)
-$497.87M
Net Income (TTM)
-$465.89M
Balance Sheet
Total Assets (Q)
$1.04B
Total Debt (Q)
$119.57M
Total Liabilities (Q)
$287.86M
Book Value Per Share (Q)
$34.28
Cash Flow
Cash from Operations (TTM)
-$455.57M
Cash from Investing (TTM)
-$274.39M
Cash from Financing (TTM)
$735.06M
Net Change in Cash (TTM)
$5.10M
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.52
7-Day Total Return
13.18%
30-Day Total Return
-1.37%
60-Day Total Return
2.59%
90-Day Total Return
9.09%
Year to Date Total Return
6.42%
1-Year Total Return
63.67%
2-Year Total Return
7.93%
3-Year Total Return
367.27%
5-Year Total Return
299.03%
52-week Low
Apr 30, 2024 - $199.40
52-week High
Feb 26, 2025 - $377.46
Valuation
Market Cap
$7.52B - Mid Cap
Enterprise Value
$6.72B
Price/Sales (TTM)
41.49
Price/Book (Q)
9.94
Dividends and Shares
Shares Outstanding
21.93M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.madrigalpharma.com
Phone Number
267 824 2827
Address
Four Tower Bridge
Suite 200 - 200 Barr Harbor Drive
West Conshohocken, PA 19428
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers... more
NASDAQ 04/30/2025 4:00PM Eastern Quotes delayed